News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
724,549 Results
Type
Article (47488)
Company Profile (301)
Press Release (676760)
Multimedia
Podcasts (68)
Webinars (12)
Section
Business (209981)
Career Advice (2404)
Deals (36113)
Drug Delivery (114)
Drug Development (82577)
Employer Resources (192)
FDA (16439)
Job Trends (15314)
News (354030)
Policy (33462)
Tag
Academia (2770)
Academic (2)
Accelerated approval (5)
Adcomms (23)
Allergies (87)
Alliances (51334)
ALS (93)
Alzheimer's disease (1429)
Antibody-drug conjugate (ADC) (132)
Approvals (16435)
Artificial intelligence (278)
Autoimmune disease (22)
Automation (16)
Bankruptcy (366)
Best Places to Work (11868)
BIOSECURE Act (20)
Biosimilars (107)
Biotechnology (205)
Bladder cancer (80)
Brain cancer (27)
Breast cancer (281)
Cancer (2298)
Cardiovascular disease (180)
Career advice (2011)
Career pathing (33)
CAR-T (161)
Cell therapy (448)
Cervical cancer (20)
Clinical research (66864)
Collaboration (863)
Company closure (1)
Compensation (535)
Complete response letters (23)
COVID-19 (2683)
CRISPR (44)
C-suite (249)
Cystic fibrosis (101)
Data (2222)
Decentralized trials (2)
Denatured (31)
Depression (45)
Diabetes (272)
Diagnostics (6541)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (47)
Drug discovery (124)
Drug pricing (109)
Drug shortages (26)
Duchenne muscular dystrophy (96)
Earnings (87650)
Editorial (40)
Employer branding (25)
Employer resources (162)
Events (116341)
Executive appointments (742)
FDA (17718)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (779)
Gene editing (111)
Generative AI (22)
Gene therapy (323)
GLP-1 (761)
Government (4600)
Grass and pollen (4)
Guidances (67)
Healthcare (19286)
Huntington's disease (25)
IgA nephropathy (29)
Immunology and inflammation (122)
Indications (29)
Infectious disease (2828)
Inflammatory bowel disease (144)
Inflation Reduction Act (10)
Influenza (51)
Intellectual property (98)
Interviews (395)
IPO (16761)
IRA (42)
Job creations (3864)
Job search strategy (1704)
Kidney cancer (10)
Labor market (41)
Layoffs (494)
Leadership (21)
Legal (8122)
Liver cancer (76)
Lung cancer (328)
Lymphoma (155)
Machine learning (7)
Management (62)
Manufacturing (317)
MASH (69)
Medical device (13588)
Medtech (13593)
Mergers & acquisitions (19898)
Metabolic disorders (710)
Multiple sclerosis (82)
NASH (22)
Neurodegenerative disease (95)
Neuropsychiatric disorders (28)
Neuroscience (1986)
NextGen: Class of 2025 (6769)
Non-profit (4677)
Now hiring (40)
Obesity (384)
Opinion (230)
Ovarian cancer (77)
Pain (92)
Pancreatic cancer (85)
Parkinson's disease (152)
Partnered (21)
Patents (237)
Patient recruitment (114)
Peanut (48)
People (59449)
Pharmaceutical (72)
Pharmacy benefit managers (18)
Phase I (20846)
Phase II (29429)
Phase III (21920)
Pipeline (1212)
Policy (146)
Postmarket research (2650)
Preclinical (9107)
Press Release (72)
Prostate cancer (107)
Psychedelics (32)
Radiopharmaceuticals (252)
Rare diseases (389)
Real estate (6256)
Recruiting (73)
Regulatory (22862)
Reports (55)
Research institute (2499)
Resumes & cover letters (418)
Rett syndrome (5)
RNA editing (5)
RSV (44)
Schizophrenia (73)
Series A (138)
Series B (87)
Service/supplier (14)
Sickle cell disease (55)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (31)
Startups (3792)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (42)
The Weekly (35)
Vaccines (723)
Venture capitalists (43)
Weight loss (253)
Women's health (37)
Worklife (19)
Date
Today (4)
Last 7 days (911)
Last 30 days (2567)
Last 365 days (33281)
2025 (10961)
2024 (36031)
2023 (40974)
2022 (52042)
2021 (56661)
2020 (55120)
2019 (47876)
2018 (36124)
2017 (33240)
2016 (32854)
2015 (38946)
2014 (32564)
2013 (27699)
2012 (29963)
2011 (30743)
2010 (29214)
Location
Africa (816)
Alabama (54)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (39791)
Australia (6575)
California (6212)
Canada (2025)
China (531)
Colorado (274)
Connecticut (276)
Delaware (149)
Europe (86948)
Florida (917)
Georgia (215)
Hawaii (1)
Idaho (58)
Illinois (553)
India (27)
Indiana (317)
Iowa (11)
Japan (163)
Kansas (106)
Kentucky (26)
Louisiana (11)
Maine (62)
Maryland (912)
Massachusetts (4658)
Michigan (238)
Minnesota (409)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (64)
New Hampshire (65)
New Jersey (1755)
New Mexico (30)
New York (1773)
North Carolina (1014)
North Dakota (9)
Northern California (2707)
Ohio (206)
Oklahoma (14)
Oregon (35)
Pennsylvania (1388)
Puerto Rico (12)
Rhode Island (33)
South America (1191)
South Carolina (23)
South Dakota (1)
Southern California (2326)
Tennessee (102)
Texas (921)
United States (23568)
Utah (185)
Virginia (148)
Washington D.C. (67)
Washington State (567)
West Virginia (3)
Wisconsin (65)
724,549 Results for "applied sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
Bio NC
Premier, Inc.’s PINC AI™ Applied Sciences and Datavant Collaborate to Enable Next-Generation Clinical Trials
PINC AI™ Applied Sciences, a division of Premier, Inc., and Datavant, the company that protects, connects and delivers the world’s health data, announce the companies are expanding their existing collaboration to help shape the future of healthcare research, advance clinical trial operations, and increase trial diversity and equity – aiming to accelerate the development of novel therapies and products for improved patient outcomes.
February 13, 2024
·
8 min read
Business
Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience Will Partner to Revolutionize Clinical Trials
Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience are announcing a landmark collaboration to accelerate global clinical trials and research innovation, improve patient outcomes and reduce health disparities.
December 12, 2023
·
5 min read
Press Releases
AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
April 29, 2025
·
4 min read
Business
New Jersey’s Life Sciences Scene Continues Expanding Beyond Big Pharma
Known as the home of big-name companies including Johnson & Johnson, New Jersey has become a destination for more and more small and midsize life sciences businesses. Choose New Jersey, Grace Therapeutics and Onyx Equities executives discuss the state’s life sciences scene.
April 10, 2025
·
6 min read
·
Angela Gabriel
Press Releases
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results
April 14, 2025
·
10 min read
Pharm Country
LANGaware Forges Transformative Collaboration with Premier, Inc.'s PINC AI™ Applied Sciences (PAS) to Revolutionize Healthcare
LANGaware, an innovative leader in digital cognitive and behavioral health diagnostics, is announcing that it will partner with Premier’s (NASDAQ: PINC) PINC AI™ Applied Sciences (PAS) to leverage Real-World Data (RWD) for the development of novel therapeutics addressing neurodegenerative and behavioral health diseases.
January 24, 2024
·
5 min read
Press Releases
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval
March 25, 2025
·
3 min read
Press Releases
Applied DNA’s LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
April 22, 2025
·
4 min read
Pharm Country
Applied DNA Announces Pricing of $12 Million Public Offering
Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced the pricing of a public offering with gross proceeds to the Company expected to be approximately $12.0 million, before deducting placement agent fees and other estimated expenses payable by the Company.
May 28, 2024
·
5 min read
1 of 72,455
Next